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Introduction
The Wnt signaling pathway plays crucial roles both in normal de-
velopment and in diseases of cell proliferation, including cancer. 
The Wnt pathway exerts its effects largely by modulating gene 
transcription (Polakis, 2000; Logan and Nusse, 2004). Cytosolic 
-catenin is the principal mediator of canonical Wnt signaling.   
In the absence of an extracellular Wnt ligand, cytosolic -catenin 
is incorporated into a cytosolic protein complex containing Axin, 
the adenomatous polyposis coli gene product (APC), and glyco-
gen synthase kinase-3 (GSK-3). Axin and APC serve as scaf-
folding proteins that enable GSK-3 to phosphorylate -catenin 
at residues 33, 37, and 41 (Liu et al., 2002), thereby targeting it 
for ubiquitination by -TrCP (-transducin repeat-containing   
homologue protein) and subsequent degradation in the protea-
some. Cytosolic -catenin protein levels are thus kept low in the 
absence of Wnt ligand stimulation. Binding of a Wnt ligand to its 
coreceptors Frizzled (Fz) and low-density lipoprotein (LDL)   
receptor-related protein (LRP) 5/6 results in the activation of   
the  Dishevelled  (Dvl)  protein,  which  then  inhibits  GSK-3– 
mediated phosphorylation of -catenin. Cytosolic -catenin is 
thus stabilized and is able to accumulate. This pool of -catenin 
translocates to the nucleus, where binding to the T cell factor 
(TCF)/lymphoid enhancer factor (LEF) transcription factors re-
sults in the activation of target gene expression (Logan and Nusse, 
2004). In addition to its role in Wnt signaling, -catenin is a com-
ponent of the cadherin-based adherens junction complexes formed   
at cell–cell adhesion sites. -Catenin binds the cytoplasmic do-
main  of  cadherin  and  acts  as  a  structural  protein  by  linking   
cell surface cadherins to the actin cytoskeleton (Daugherty and 
Gottardi, 2007). By sequestering -catenin at the membrane, cad-
herins modulate the signaling properties of cytosolic -catenin, 
creating a finely tuned balance between Wnt signaling and cell–
cell adhesion (Heasman et al., 1994; Cox et al., 1996; Fagotto   
et al., 1996).
The tetraspanin transmembrane proteins possess four 
membrane-spanning domains. Tetraspanins engage in a very 
wide range of specific molecular interactions that result in the 
formation in the plane of the membrane of tetraspanin-enriched 
microdomains (TEM). Tetraspanins have been implicated in a 
multitude of biological processes, such as cell adhesion, migra-
tion, cell fusion, and signal transduction through their associated 
partner molecules (Hemler, 2005; Levy and Shoham, 2005).   
Several members of this family influence tumor growth and 
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D82 and CD9 are tetraspanin membrane proteins 
that can function as suppressors of tumor metastasis. 
Expression of CD9 and CD82 in transfected cells 
strongly suppresses -catenin–mediated Wnt signaling   
activity and induces a significant decrease in -catenin   
protein levels. Inhibition of Wnt/-catenin signaling is   
independent of glycogen synthase kinase-3 and of the 
proteasome- and lysosome-mediated protein degradation 
pathways. CD82 and CD9 expression induces -catenin 
export via exosomes, which is blocked by a sphingomyelinase 
inhibitor, GW4869. CD82 fails to induce exosome re-
lease of -catenin in cells that express low levels of   
E-cadherin. Exosome release from dendritic cells generated 
from CD9 knockout mice is reduced compared with that 
from wild-type dendritic cells. These results suggest that 
CD82 and CD9 down-regulate the Wnt signaling pathway 
through the exosomal discharge of -catenin. Thus, exo-
somal packaging and release of cytosolic proteins can mod-
ulate the activity of cellular signaling pathways.
Exosome release of -catenin: a novel mechanism 
that antagonizes Wnt signaling
Arthit Chairoungdua,
1,2 Danielle L. Smith,
1 Pierre Pochard,
1 Michael Hull,
1 and Michael J. Caplan
1
1Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, CT 06510
2Department of Physiology, Faculty of Science, Mahidol University, Bangkok 10400, Thailand
© 2010 Chairoungdua et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after the pub-
lication date (see http://www.rupress.org/terms). After six months it is available under a 
Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, 
as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
T
H
E
J
O
U
R
N
A
L
O
F
C
E
L
L
B
I
O
L
O
G
YJCB • VOLUME 190 • NUMBER 6 • 2010   1080
protein levels in both cytosolic and nuclear fractions in HEK   
293T cells (Fig. 1 B).
In addition to CD82, loss of expression of tetraspanin mole-
cules CD9 or CD63 in tumor cells also correlates with poor prog-
nosis and increased metastasis (Higashiyama et al., 1995; Radford 
et al., 1995; Boucheix et al., 2001). We therefore examined 
whether CD9 and CD63 also regulate Wnt/-catenin signaling. 
Similar to the behavior of CD82, expression of CD9 suppressed 
TCF promoter-driven luciferase activity and reduced the expres-
sion levels of -catenin protein in both cytosolic and nuclear   
fractions (Fig. 1, A and B). However, CD63 did not suppress the 
luciferase activity stimulated by -catenin in HEK 293T cells 
(Fig. 1 A). Consistent with the luciferase assay result, the expres-
sion  levels  of  -catenin  were  unchanged  in  CD63-expressing 
cells (Fig. 1 B). This was not due to low levels of CD63 expres-
sion because exogenous CD63 protein was abundantly expressed 
in these cells (unpublished data). CD9 and CD82 expression also 
inhibits Wnt/-catenin signaling activated by Wnt3a conditioned 
medium (Fig. S1).
To exclude any influence of variable plasmid transfection 
efficiencies, we used pNRTIS-21-CD9 and pNRTIS-21-CD82 
constructs, in which the expression of the tetraspan is under the 
control of the Tet-Off promoter (Tenev et al., 2000). The expres-
sion levels of CD9 and CD82 were high when the cells were cul-
tured in the absence of doxycycline, but were markedly reduced 
when cells were cultured in the presence of 100 ng/ml of the 
drug (Fig. 1, D and F). The Wnt/-catenin activity was substan-
tially inhibited in cells cultured in the absence of doxycycline 
and was partially rescued when cells were treated with doxy-
cycline (Fig. 1, C and E). Consistent with these Wnt/-catenin 
activity measurements, the expression levels of three different 
forms of -catenin, including total -catenin, dephosphorylated 
-catenin (anti-ABC), and phosphorylated -catenin, were al-
most identical in untransfected cells and in doxycycline-treated 
CD9- or CD82-expressing cells. These data demonstrate that tetra-
span expression alters the size of the total -catenin population 
rather than simply affecting its phosphorylation status. The quan-
tity of -catenin mRNA was not affected by expression of CD9 
or CD82 (unpublished data). The inhibition of Wnt/-catenin 
signaling by CD9 and CD82 was future confirmed by immuno-
fluoresence in CHO cells. As shown in Fig. 2 A, -catenin immuno-
staining was predominantly localized in the nucleus when cells 
were cotransfected with either empty vector or with a plasmid 
expressing CD63. In contrast, upon coexpression with CD9 or 
CD82, the -catenin staining was markedly reduced, particularly 
in nucleus, and manifest instead a punctuate peri-plasma mem-
brane pattern. Collectively, these results suggest that CD9 and 
CD82  antagonize  the  canonical  Wnt/-catenin  signaling 
pathway by promoting a reduction in cellular levels of the   
-catenin protein.
Knockdown of endogenous CD9 activates 
Wnt/-catenin signaling
To assess the role of endogenous CD9 expression in suppress-
ing basal levels of Wnt signaling, two shRNA constructs target-
ing the human CD9 sequence and a scrambled control sequence 
were used as described in Materials and methods. As shown 
progression. Indeed, the tetraspan CD82 was first identified as a 
tumor suppressor gene. Down-regulation of CD82 expression 
has been strongly associated with poor prognosis in patients with 
several types of cancer (Tonoli and Barrett, 2005). In addition, a 
microarray analysis showed that CD9 expression in tumor cells 
correlated with down-regulation of several Wnt family genes and 
their targets, suggesting that CD9 may act as an upstream nega-
tive regulator in the Wnt signaling pathway (Huang et al., 2004). 
Previous immunoelectron microscopic studies have shown that 
several members of the tetraspanin family, including CD37, 
CD53, CD63, CD81, and CD82, are enriched in exosomes (Escola 
et al., 1998). However, the functional role of tetraspanins in exo-
somes remains unknown.
Exosomes are small membrane vesicles (30–100 nm in di-
ameter) with a density of 1.13 g/ml that are secreted by various 
cells. Exosomes originate from the inward budding of an endo-
some’s limiting membrane into its lumen, resulting in the forma-
tion of a multivesicular body (MVB). The outer membranes of 
MVBs can fuse with the plasma membrane and release their intra-
luminal vesicles to the extracellular space as exosomes (Théry   
et al., 2002; Lakkaraju and Rodriguez-Boulan, 2008; Schorey 
and Bhatnagar, 2008). Exosome composition varies depending 
on the cell type of origin. Exosome functions also depend on the 
cell types from which they are derived and their composition.   
As mentioned above, tetraspanins are enriched in the membranes 
of exosomes. In addition, exosomes also contain a number of   
tetraspan-interacting proteins, such as the major histocompatibility 
complexes (MHC) class I and II (Escola et al., 1998; Schorey and 
Bhatnagar, 2008).
In present study, we show that CD82 and CD9 expression 
profoundly inhibits Wnt signaling. CD82 and CD9 expression 
reduces the cellular pool of -catenin by enhancing the exosome- 
associated export of -catenin from the cell. The exosome- 
associated  release  of  -catenin  requires  the  expression  of 
E-cadherin, and CD82 was coimmunoprecipitated with the   
E-cadherin–-catenin complex. Using tissue from CD9 knock-
out animals, we present data suggesting that tetraspans regulate 
exosome biogenesis in vivo.
Results
Tetraspanins suppress canonical  
Wnt/-catenin signaling by decreasing  
levels of -catenin
To address the molecular mechanisms through which CD82 
may regulate Wnt/-catenin signaling, we performed a TOP-
flash luciferase assay in HEK 293T cells. The data were nor-
malized by cotransfecting with a Renilla luciferase-encoding 
plasmid, which was used to control for variations in transfection 
efficiency. In this cell line, -catenin expression led to up- 
regulation of the canonical Wnt/-catenin activity as indicated 
by increased luciferase activity (Fig. 1 A). When CD82 was co-
transfected with -catenin, we found that the luciferase ac-
tivity was substantially reduced. We next tested whether CD82 
inhibited the canonical Wnt/-catenin signaling pathway by 
regulating the level of -catenin expression. We found that 
CD82 expression induced a significant decrease in -catenin 1081 A novel mechanism that inhibits Wnt signaling • Chairoungdua et al.
active -catenin mutants, S45 and S33Y, which are insensitive 
to CK-1 and GSK-3–mediated phosphorylation, respectively, 
and thus are not substrates for proteasome-induced protein deg-
radation (Liu et al., 2002). Our data indicated that Wnt/-catenin 
signaling stimulated by these stabilized -catenin proteins was 
susceptible to inhibition induced by the overexpression of CD9 
and CD82 (Fig. 3 A; Fig. S2 A). This repression was associated 
with a decrease in levels of -catenin protein in both the cyto-
solic and nuclear fractions (Fig. 3 B; Fig. S2 B). We also used 
LiCl  and  SB216763  to  specifically  inhibit  GSK-3  activity. 
LiCl and SB216763 treatment resulted in the activation of the 
TOPflash luciferase reporter assay and led to the accumulation 
of -catenin in HEK 293T cells. However, CD9 and CD82 were 
still able to inhibit Wnt/-catenin activity and to reduce the cel-
lular levels of the -catenin protein in cells treated with these 
GSK-3 inhibitors (Fig. 3 C; Fig. S2, C and D). In contrast, 
in Fig. 2 B, the expression level of endogenous CD9 was re-
duced when HeLa cells were transfected with shRNA targeted 
to CD9. In contrast, scrambled control shRNA did not reduce 
the expression level of endogenous CD9 (Fig. 2 B). Knockdown 
of endogenous CD9 resulted in an increase in the level of acti-
vated Wnt/-catenin activity (Fig. 2 B). These results further 
confirm the inhibitory effects of native CD9 on endogenous 
Wnt/-catenin signaling.
CD9 and CD82 induce GSK-3-, 
proteasome-, and lysosome-independent 
antagonism of canonical Wnt signaling
Phosphorylation of -catenin by GSK-3 leads to -TrCP bind-
ing, which results in -catenin degradation. Thus, we next tested 
whether CD9 and CD82 inhibition of Wnt/-catenin signaling 
involves GSK-3. Toward this end, we used two constitutively 
Figure  1.  Effects  of  tetraspanins  on  TCF/LEF  reporter 
activity and levels of -catenin. (A) CD9 and CD82 ex-
pression inhibits -catenin signaling. HEK 293T cells were 
transiently cotransfected with TOPflash, Xpress-tagged   
-catenin, the indicated tetraspanins, and the Renilla lucif-
erase vector. Activity of the -catenin signaling pathway 
was quantified by measuring relative firefly luciferase   
activity units (RLUs) normalized to Renilla luciferase. Data 
are presented as the fold change as compared with the 
control condition (cells transfected with pcDNA3.1 empty 
vector  alone).  (B)  CD9  and  CD82  expression  reduces 
cytosolic and nuclear pools of -catenin. HEK 293T cells 
were harvested 24 h after transient transfection with the 
indicated plasmids. Cell lysates were analyzed by West-
ern blotting using anti-Xpress (-catenin) and anti–-actin 
antibodies. (C–F) Inducible expression of tetraspanins in-
hibits the activity of -catenin–mediated signaling. HEK 
293T cells were transiently cotransfected with a cDNA 
encoding CD9 or CD82 under the control of a Tet-Off pro-
moter, TOPflash, -catenin, and Renilla luciferase vector. 
After culture in the presence (DOX (+)) and absence (DOX 
()) of 100 ng/ml of doxycycline for 48 h, cells were 
harvested for luciferase-based TOPflash assay of Wnt sig-
naling (C and E) and immunoblotted with the indicated 
antibodies (D and F). Luciferase data are presented as 
the fold change as compared with the control condition 
(untransfected cells).JCB • VOLUME 190 • NUMBER 6 • 2010   1082
Figure 2.  Localization of -catenin in CHO cells. (A) CHO cells were transfected with the indicated plasmids and immunostained for tetraspanins and -catenin 
using an anti-FLAG and anti-dephosphorylated -catenin (anti-ABC), respectively. In control and CD63-transfected cells, -catenin immunostaining was predomi-
nantly localized in the nucleus (arrowhead). Upon coexpression with CD9 and CD82, -catenin staining was decreased in the nucleus and was associated 
instead with a punctuate plasma membrane pattern. Bar, 10 µm. (B) Knockdown of CD9 stimulates Wnt/-catenin signaling. HeLa cells were cotransfected with 
shRNA targeted for CD9 sequences or with a scrambled control sequence as described in Materials and methods, as well as with plasmids encoding -catenin, 
TOPflash, and Renilla luciferase. After 48 h cells were harvested and analyzed by Western blotting using anti-dephosphorylated -catenin (anti-ABC) and anti-
CD9. -Actin was used as a loading control (left). Corresponding lysates were used for luciferase assay (right). Data are shown as the fold change compared 
with control (cells transfected with empty vector). Data are presented as mean ± SEM. *, P < 0.05; ***, P < 0.005 compared with control (t test).1083 A novel mechanism that inhibits Wnt signaling • Chairoungdua et al.
lysosome.  We  thus  treated  cells  with  the  lysosome  inhibitor   
bafilomycin A (250 nM) for 16 h. The reductions in the levels of 
-catenin present in the cells expressing CD9 and CD82 were 
not reversed after treatment with this lysosome acidification in-
hibitor (Fig. 4 B). These results suggest that the degradation of 
-catenin  was  not  mediated  through  the  lysosome-associated 
protein degradation pathway. Collectively, these results suggest 
that CD9 and CD82 inhibit the canonical Wnt/-catenin signal-
ing and reduce cellular -catenin levels through a mechanism 
that is independent of GSK-3 and of either the proteasome- or 
lysosome-mediated protein degradation pathways.
Exosomes purified from CD9- and CD82-
transfected cells are enriched for -catenin
Exosomes are small (30–100 nm in diameter) membrane-bound 
vesicles released by a variety of cell types. As mentioned above, 
CD63 did not reduce either the Wnt/-catenin activity or the 
level of -catenin protein under these circumstances.
The data presented in Fig. 3 demonstrate that inhibitory   
effects of CD9 and CD82 on Wnt/-catenin signaling do not   
involve the activity of GSK-3. We thus wished to determine 
whether CD9- and CD82-mediated destabilization of -catenin 
proceeds through an alternative GSK-3–independent proteasome- 
associated protein degradation pathway and, as such, would 
be relieved in the presence of the proteasome inhibitor clasto-
lactacystin. As shown in Fig. 4 A, HEK 293T cells were cotrans-
fected with -catenin and the indicated plasmids and then treated 
with 10 µM clasto-lactacystin for 16 h. Treatment with the protea-
some inhibitor increased the basal levels of -catenin. However, 
CD9 and CD82 markedly suppressed this level of -catenin ex-
pression. We next wondered whether CD9 and/or CD82 would 
mediate -catenin degradation through a pathway involving the 
Figure 3.  CD9 and CD82 inhibition of Wnt/-catenin signaling is GSK-3 independent. (A) CD9 and CD82 but not CD63 inhibit TOPflash activity stimu-
lated by mutant S33Y–-catenin. 24 h after transfection with the indicated plasmids, cells were harvested for TOPflash luciferase assay. Data are presented 
as the fold change as compared with the control condition (cells transfected with pcDNA3.1 empty vector alone). (B) CD9 and CD82 expression reduced 
cytosolic and nuclear pools of the mutant S33Y–-catenin protein. Cell fractions prepared from HEK 293T cells transfected with the indicated plasmids 
were immunoblotted using anti-Xpress (-catenin) and anti–-actin antibodies. (C) Effects of GSK-3 inhibitors on -catenin levels. 12 h after transfection 
with the indicated plasmids, HEK 293T cells were treated with 50 mM NaCl, 50 mM LiCl, 20 µM SB216763, or DMSO (control) for 12 h. Lysates were 
blotted with anti–-catenin and anti-dephosphorylated -catenin (anti-ABC). -Actin was used as a loading control.JCB • VOLUME 190 • NUMBER 6 • 2010   1084
the exosome fraction, which did contain the two exosomal pro-
teins, HSP70 and flotillin. The exosome fraction also did not 
contain apoptotic vesicles, because the apoptotic marker cyto-
chrome c was not detected in the exosome fractions. These re-
sults suggest that the contamination of the exosome fraction 
with material derived from these compartments or from apop-
totic cells is minimal.
Interestingly, the results clearly demonstrate the pres-
ence of -catenin in exosomes isolated from CD9- and CD82-
transfected  HEK  293T  cells,  whereas  the  exosomes  isolated 
from empty vector and CD63-transfected cells contain far lower 
amounts -catenin (Fig. 5 B). Approximately 60% of the total 
cellular -catenin pool was detected in exosomes isolated from 
CD9 (57.25 ± 4.25, n = 3)- and CD82 (56.91 ± 5.71, n = 3)-
transfected HEK 293T cells. Exosome content in preparations 
from both the tetraspan-transfected and vector alone cells was 
confirmed by the presence of flotillin, a lipid raft protein known 
to be localized in exosomes. To further confirm the roles of CD9 
and CD82 in facilitating the transport of -catenin into exo-
somes, exosome fractions isolated from HEK 293T cells tran-
siently transfected with cDNAs encoding CD9 and CD82 under 
the control of a Tet-Off promoter were analyzed using Western 
blotting. Cells were cultured in the presence (DOX; +) and ab-
sence (DOX; ) of 100 ng/ml doxycycline for 48 h. As ex-
pected, in the presence of doxycycline CD9 and CD82 were not 
detected in exosomes, consistent with the very low levels of 
CD9 and CD82 expression in these cells. In contrast, there was 
dramatic  enrichment  of  -catenin  in  exosomes  produced  by 
CD9- and CD82-expressing cells that were grown in the absence 
of doxycycline (Fig. 5 C). To determine whether the pool of   
-catenin that is recovered with the exosome fraction is con-
tained within the lumens of vesicular structures, we treated the 
exosome fraction with trypsin in the presence or absence of de-
tergent and assessed the quantity of intact -catenin associated 
with this material by Western blotting. In the absence of deter-
gent, the exosome-associated -catenin was fully protected 
from trypsin degradation, whereas -catenin was completely 
degraded when detergent was added (Fig. S3 A). These data 
demonstrate that the -catenin protein recovered with the en-
riched exosome fraction is contained within the lumens of the 
exosomal vesicles.
Several  signaling  and  trafficking  pathways  have  been 
shown to influence exosome production. A p53-regulated gene 
product, TSAP6, has been shown to increase exosome produc-
tion in cells subjected to DNA damage in a p53-dependent man-
ner (Yu et al., 2006). However, expression of TSAP6 appears to 
have no affect on CD82-mediated exosome production and se-
cretion (Fig. S3 B). The ESCRT complex (endosomal sorting 
complex required for transport) can play a role in exosome re-
lease (Géminard et al., 2004). Expression of dominant-negative 
forms of obligate ESCRT components Vps4 and Tsg101, how-
ever, did not prevent CD82-induced -catenin release into exo-
somes (Fig. S3 C). Purified exosomes are enriched in ceramide. 
Inhibition  of  ceramide  formation  through  treatment  of  cells 
with the sphingomyelinase (nSMase) inhibitor GW4869 mark-
edly reduces exosome release (Trajkovic et al., 2008). Thus,   
we tested the effects of the nSMase inhibitor on the exosomal 
tetraspanins  are  enriched  in  the  membranes  of  exosomes.   
To test the possibility that tetraspanins reduce cellular levels of 
-catenin by facilitating its export via exosomes, a number of 
experiments were performed. Standard protocols were used to 
isolate exosomes from media that was bathing cultured cells 
(Thery et al., 2006) throughout 48 h after their transfection.   
After several centrifugation steps as outlined in Materials and 
methods,  exosomes  were  pelleted  and  analyzed  by  electron   
microscopy and Western blotting. Electron microscopy of a nega-
tively stained exosome preparation revealed “cup-shaped” 
membrane vesicles with diameters of 30–100 nm (Fig. 5 A), 
which corresponds to the previously characterized ultrastruc-
tural  morphology  of  exosomes  (Février  and  Raposo,  2004).
Interestingly, vesicles were detected in culture medium har-
vested from all conditions. However, more exosomes were puri-
fied from CD9- and CD82-transfected HEK 293T cells. These 
results suggest that CD9 and CD82 expression enhances exo-
some production by these cells. Aliquots of protein extracted 
from cells (10 µg) and of protein extracted from pelleted exo-
somes (2 µg) were subjected to Western blot analysis using 
antibodies specific for the known exosomal proteins HSP70 and 
flotillin-1, or for markers specific to other subcellular compart-
ments, including early endosomes (EEA1), endoplasmic reticu-
lum (calnexin), TGN (-adaptin), and a marker of apoptotic 
cells (cytochrome c). Western blot analysis (Fig. 5 B) shows the 
enrichment of tetraspanins in exosome fractions. In addition, 
ER, TGN, and early endosomal proteins were not detected in 
Figure 4.  CD9- and CD82-mediated -catenin destabilization is indepen-
dent from the proteasome- and lysosome-associated protein degradation 
pathways. HEK 293T cells cotransfected with the indicated plasmids were 
treated with 10 µM clasto-lactacystin (A), 250 nM bafilomycin A (B), or 
DMSO vehicle alone for 16 h before being harvested for Western blotting 
using anti-Xpress antibody (-catenin). -Actin was used as a loading con-
trol. CD9 and CD82 were still able to reduce -catenin protein levels in the 
presence of both inhibitors.1085 A novel mechanism that inhibits Wnt signaling • Chairoungdua et al.
Figure 5.  -catenin is secreted into exosomes. (A) Electron microscopy of extracellular exosomes secreted by HEK 293T cells. Exosomes were isolated by 
sequential centrifugation steps as described in Materials and methods from HEK 293T cells transfected with the indicated plasmids. Control cells were trans-
fected with empty vector. Bar, 200 nm. (B) -Catenin, E-cadherin, and tetraspanins are secreted into exosomes. Total lysate (T) and exosome (E) fractions 
purified from HEK 293T cells transfected with the indicated plasmids were analyzed by Western blotting using the indicated antibodies. EEA1, calnexin, 
and -adaptin are membrane markers for early endosomes, ER, and TGN, respectively. Cytochrome c was used as a marker for apoptotic cell fragments. 
(C) Exosome release of -catenin is dependent on CD9 and CD82. HEK 293T cells were transiently transfected with a cDNA encoding CD9 and CD82 
under control of the Tet-Off promoter or empty vector as control. After being cultured in the presence (DOX (+)) and absence (DOX ()) of 100 ng/ml of 
doxycycline for 48 h, total lysate (T) and exosome (E) fractions were analyzed by Western blotting using the indicated antibodies. The exosomal protein, 
flotillin, was used as a loading control. (D) Exosome release of -catenin is reduced after treatment with a sphingomyelinase (nSMase) inhibitor. HEK 293T 
cells were transfected with CD82 or with empty vector as control and then treated with 5 µM GW4869 or DMSO for 16 h. Total lysate (T) and exosome 
(E) fractions were blotted with anti–-catenin and anti–flotillin-1 antibodies.
export  of  -catenin.  After  treatment  with  GW4869,  total 
exosome release was reduced, as indicated by the reduction 
of flotillin recovered in the exosome fraction. Consistent with 
the  reduction  in  exsosome  release,  a  marked  reduction  in 
exosome release of -catenin was also observed (Fig. 5 D). 
Collectively, these results indicate that CD9 and CD82 reduce JCB • VOLUME 190 • NUMBER 6 • 2010   1086
cells stably transfected with empty vector rather than vector en-
coding CD82 (Fig. S4 A). In addition, -catenin was not de-
tected in immunoprecipitates from HEK 293T cells transiently 
transfected with a vector encoding CD63 (Fig. S4 B). E-cadherin 
and -catenin could also be coimmunoprecipitated with CD82 
from purified exosomes dissolved in 0.3% CHAPS lysis buf-
fer (Fig. 6 B).
To determine whether E-cadherin is required for the 
transport of -catenin into exosomes, we examined the exosome- 
associated release of -catenin in A431D cells, in which ex-
pression of endogenous E-cadherin is absent (Lewis et al., 
1997). Both -catenin and E-cadherin were readily detected in 
exosomes purified from culture medium of cells cotransfected 
with CD82 and E-cadherin (Fig. 6 C). The -catenin protein 
was barely detected in exosomes derived from A431D cells 
cotransfected with -catenin and either CD82 or E-cadherin 
alone. The quantity of -catenin detectable in cell lysates is not 
different in cells cotransfected with both CD82 and E-cadherin, 
as compared with that found in cells expressing CD82 alone 
(Fig. 6 C, lanes 3 and 4). Like A431D cells, CHO cells express 
little or no E-cadherin (Chausovsky et al., 2000) and similar   
the cytoplasmic pool of -catenin by facilitating this protein’s 
transport into exosomes.
Exosome release of -catenin  
requires E-cadherin
As shown in Fig. 5 B, E-cadherin was detected in exosome frac-
tions purified from cells transfected with CD9 and CD82.   
E-cadherin is a type I, single-pass transmembrane glycoprotein 
that mediates Ca
2+-dependent intercellular adhesion. The cyto-
plasmic region of E-cadherin is linked to the actin cytoskeleton 
through - and -catenin (Daugherty and Gottardi, 2007).   
A number of CD82- and CD9-interacting proteins have been 
detected in exosomes (Escola et al., 1998; Schorey and Bhatnagar, 
2008). To investigate the possibility of an interaction between 
tetraspanins and the E-cadherin complex, HEK 293T cells sta-
bly expressing CD82 were generated. As shown in Fig. 6 A,   
E-cadherin and -catenin could be coimmunoprecipitated with 
CD82 from lysates of cells dissolved in either 0.3% CHAPS   
or 1% Brij 96. The total quantity of E-cadherin, -catenin, 
and CD82 present in the cell lysate is shown in Fig. 6 A (right). 
-Catenin was not detected in immunoprecipitates from control 
Figure 6.  E-cadherin–dependent exosome release of -catenin. (A) CD82 interacts with the E-cadherin–-catenin complex. HEK 293T cells stably express-
ing CD82 or empty vector were transfected with E-cadherin-GFP and -catenin. 24 h after transfection, cells were lysed with the indicated lysis buffer and 
immunoprecipitated with anti-FLAG M2 affinity gel. The immunoprecipitated samples were washed with the indicated concentration of NaCl, followed by 
Western blotting with anti-GFP and anti–-catenin antibodies (left). Total cell lysates were subjected to Western blotting with the indicated antibodies (right). 
(B) CD82 interacts with the E-cadherin–-catenin complex in exosomes. Exosomes were purified from HEK 293T cells stably expressing CD82 or empty vec-
tor. Exosome fractions were lysed with 0.3% CHAPS lysis buffer and immunoprecipitated with anti-FLAG M2 affinity gel. The immunoprecipitated samples 
were washed with lysis buffer, followed by Western blotting with the indicated antibodies. (C) E-cadherin is required for CD82-induced exosome release 
of -catenin. A431D cells were cotransfected with the indicated plasmids. After 48 h, total lysate and exosome fractions were purified and analyzed by 
Western blotting using the indicated antibodies.1087 A novel mechanism that inhibits Wnt signaling • Chairoungdua et al.
In the present study we have demonstrated a novel path-
way for the cellular export of -catenin. -Catenin is released in 
association with exosomes and this export is enhanced by CD82 
and CD9 expression. Exosomes are small (30–100 nm in diam-
eter), membrane-bound vesicles released by variety of cells. 
Exosomes are now thought to play key roles in cell-to-cell com-
munication, antigen presentation, and in the pathogenesis of   
retroviral infections and prion diseases. Interestingly, tetraspanin 
proteins are highly enriched in exosomes (Escola et al., 1998; 
Théry et al., 2002; Schorey and Bhatnagar, 2008). Consistent 
with previous studies, our purified exosomes are enriched for all 
of the tetraspan proteins tested. In addition, although ER, TGN, 
and early endosomal marker proteins were not detected in puri-
fied exosomes, this fraction did contain two well-characterized 
exosomal proteins, flotillin 1 and HSP70. Furthermore, -catenin 
has been identified in exosomes from immature DCs and mature 
DCs by proteomic analysis (Segura et al., 2005). However, the 
mechanisms through which tetraspanins influence the production, 
content, and release of exosomes are largely unknown. The path-
ways for endosome formation and release may be either ESCRT 
dependent (de Gassart et al., 2004; Simons and Raposo, 2009) or 
independent. We found that the expression of dominant-negative 
forms of the ESCRT components Vps4 and Tsg101 (Sun et al., 
1999; Garrus et al., 2001) had no effect on CD82-mediated exo-
some secretion of -catenin. A recent study has demonstrated that 
budding of exosome vesicles into the lumen of the endosome re-
quires the sphingolipid ceramide. The release of exosomes was 
reduced after the inhibition of ceramide synthesis (Trajkovic et al., 
2008). Consistent with these data, the exosome-associated release 
of -catenin was reduced after inhibition of neutral sphingo-
myelinase (nSMase). Thus, our results strongly suggest that CD82 
and CD9 stimulate -catenin secretion via the ceramide-dependent 
exosomal pathway.
These results raise fundamental questions regarding the 
mechanism by which -catenin is targeted to exosomes. CD82- 
and CD9-interacting proteins, such as the major histocompati-
bility complex (MHC) class I and II molecules, among others 
(Escola et al., 1998; Schorey and Bhatnagar, 2008), have been 
identified in exosomes (Escola et al., 1998). These observations 
suggest that the trafficking of -catenin to exosomes may re-
quire its direct or indirect interaction with the tetraspanins. Inter-
estingly, E-cadherin was also detected in exosomes in cells that 
overexpressed either CD82 or CD9. Indeed, cadherin has been 
identified in immature DC– and mature DC–derived exosomes 
by proteomic analysis (Segura et al., 2005). -Catenin binds to 
the cytoplasmic domain of E-cadherin and links cadherin to the 
actin cytoskeleton through -catenin (Daugherty and Gottardi, 
2007). It has been shown that E-cadherin can sequester the sig-
naling pool of -catenin and thus blunt its capacity to participate 
in the Wnt pathway. Overexpression of cadherin in Xenopus  
embryos reduced the level of -catenin in the cytoplasm and   
nucleus by recruiting it to the plasma membrane (Fagotto et al., 
1996), demonstrating that cadherin can act as a negative regula-
tor of Wnt signaling. Our data demonstrate that E-cadherin and 
-catenin were coimmunoprecipitated with CD82 and that   
E-cadherin is required in order for CD82 expression to drive the 
exosomal discharge of -catenin. These observations suggest an 
results were obtained when CHO cells were induced to express 
wild-type -catenin in the presence or absence of E-cadherin 
(Fig. S5 A). Approximately 70% of the cellular pool of -catenin 
was detected in exosomes isolated from E-cadherin and CD82-
transfected CHO cells (68.90 ± 3.08, n = 4). E-cadherin–dependent 
discharge of -catenin–S33Y from CHO cells was also ob-
served (Fig. S5 B), further confirming that exosome release of 
-catenin is independent of any need for GSK-3 phosphoryla-
tion. Collectively, these results indicate that E-cadherin can sta-
bilize cytosolic -catenin and is required to mediate -catenin’s 
release into exosomes.
Reduction of exosome release in CD9 
knockout mice
To investigate the role of tetraspanins in exosome release in vivo, 
bone marrow dendritic cells (BMDCs) were generated from wild-
type and CD9 knockout mice as described in Materials and 
methods. BMDC-derived exosomes were purified from culture 
medium on d 7 and analyzed by Western blotting using anti-flotillin 
antibody. As shown in Fig. 7 A, BMDCs generated from CD9 
knockout mice secreted a smaller quantity of exosomes as com-
pared with BMDCs generated from wild-type mice. Quantitation 
of transmission electron micrographs of these exosome fractions 
confirmed these results, demonstrating that the quantity of mor-
phologically recognizable exosomes released from the CD9 null 
cells is one third of that released from wild-type cells (Fig. S5 C). 
These data support the concept that tetraspanins play a central 
role in exosome release.
Discussion
Our work demonstrates a novel role for tetraspanins in inhibiting 
Wnt/-catenin signaling through the reduction of the cellular 
pool of -catenin. The reduction of the cellular pool of -catenin 
that is mediated by CD9 and CD82 expression occurred through 
a mechanism that is independent of GSK-3 and either the 
proteasome- or lysosome-induced protein degradation pathways.   
It has been demonstrated that cellular -catenin levels are regu-
lated by two different mechanisms. In addition to the GSK-3–
dependent pathway, recent studies suggest that -catenin levels 
are regulated by a phosphorylation-independent pathway, which 
is initiated by an increase in Siah-family protein expression (Liu 
et al., 2001; Matsuzawa and Reed, 2001). However, we found 
that the endogenous level of the Siah-1 transcript did not change 
after expression of CD82 (unpublished data). Nuclear import/ 
export of -catenin is a crucial step in regulating Wnt signaling 
(Gordon and Nusse, 2006). We find that CD82 and CD9 expres-
sion reduced the level of -catenin detectable in the nucleus. 
This is likely due to the reduction of total -catenin rather than 
to any effect on the nuclear import/export mechanism. CD82 and 
CD9 did not affect the level of -catenin transcripts or the rate of 
-catenin synthesis, as assessed by pulse-chase analysis (unpub-
lished data). Instead, CD82 and CD9 reduced the levels of both 
dephosphorylated and phosphorylated -catenin, suggesting 
that CD82 and CD9 act through a novel mechanism rather than 
through any of the known kinase-dependent mechanisms, to reg-
ulate the level of -catenin.JCB • VOLUME 190 • NUMBER 6 • 2010   1088
Figure 7.  Effects of CD9 on Wnt/-catenin signaling and exosome release in vivo. (A) Reduction of BMDC-derived exosomes from CD9 knockout mice. 
Exosomes were purified from BMDCs derived from CD9 wild-type and knockout mice as described in Materials and methods and analyzed by Western blot-
ting using the indicated antibodies. BMDC lysates were immunoblotted with anti-CD9 as shown in the bottom panel. (B) CD82 expression inhibits -catenin 
signaling and facilitates the exosome release of -catenin in PC3 cells. PC3 cells were transiently cotransfected with the indicated plasmids and with the 
TOPflash and the Renilla luciferase vectors. Activity of the -catenin signaling pathway was quantified by measuring relative firefly luciferase activity units 
(RLUs) normalized to Renilla luciferase and expressed as fold change in the luciferase signal (top panel). In the bottom panel, Western blots of total lysates 
and exosome fractions were purified from PC3 cells transiently transfected with indicated plasmids. CD82 expression increased the exosome release of 
-catenin by a factor of 3. (C) A novel role for tetraspanins in the regulation of Wnt/-catenin signaling. At steady state, tetraspanins are organized in a 
signaling complex with E-cadherin at the plasma membrane. This signaling complex, including tetraspanins, E-cadherin, and -catenin, is internalized and 
delivered to early endosomes. Exosome biogenesis begins with outward vesicle budding at the limiting membrane of endosomes, generating intraluminal 
vesicles (ILVs). These exosome-containing endosomes eventually mature into late endosomes, also known as mutivesicular bodies (MVBs). These MVBs then 
fuse with plasma membrane and release their intraluminal vesicles, referred to as exosomes, which contain -catenin. The exosome targeting of -catenin 
causes a reduction in the intracellular pool of -catenin and therefore reduces Wnt/-catenin signaling.
entirely new pathway through which E-cadherin can act as a 
negative regulator of canonical Wnt signaling. It remains to   
be determined whether and how both the interaction between 
tetraspanins and the E-caherin–-catenin complex and the conse-
quent targeting of this complex to exosomes are regulated at the 
molecular level. It should be noted that the relative concentration 1089 A novel mechanism that inhibits Wnt signaling • Chairoungdua et al.
targeting of -catenin causes a reduction in the intracellular pool 
of -catenin, which therefore reduces Wnt/-catenin signaling. 
Consistent with roles of CD82 and CD9 as suppressors of tumor 
metastasis, CD82 is frequently down-regulated in advanced 
stages of cancer, and loss of CD82 has been strongly associated 
with poor prognosis in several human cancers (Dong et al., 1995; 
Tonoli and Barrett, 2005). The PC3 line of metastasic prostate 
cancer cells lack CD82 expression (Sridhar and Miranti, 2006). 
We found that restoration of CD82 expression in PC3 cells in-
hibited Wnt/-catenin signaling and induced the exosome re-
lease of -catenin (Fig. 7 B). Indeed, CD82 was identified in   
a genome-wide siRNA screen to be a modulator of the Wnt/ 
-catenin signaling pathway (Major et al., 2008). Down-regulation 
of CD9 also correlates with tumor progression in several types 
of cancer (Zöller, 2009). In addition, CD9 expression induces 
down-regulation of several Wnt family genes and their targets, 
as revealed by microarray analysis (Huang et al., 2004). Our re-
sults suggest that CD82 and CD9 might suppress tumor meta-
stasis through down-regulation of the Wnt signaling pathway via 
a novel mechanism that leads ultimately to the exosomal dis-
charge of -catenin.
Materials and methods
Plasmids, antibodies, and reagents
The sequences encoding human CD9, CD63, and CD82 were amplified by 
PCR and inserted by subcloning into pcDNA3.1. FLAG tags were intro-
duced at the N termini of these constructs. Xpress-tagged -catenin was gen-
erated by PCR and cloned into the BamHI and NotI sites of pcDNA4/HisMax-A 
vector in the correct reading frame. To generate the -catenin–pcDNA3.1 
expression vector, Xpress-tagged -catenin was digested with BamHI and 
NotI and cloned into the BamHI and NotI sites of the pcDNA3.1(+) vector. 
To generate the CD9 and CD82 bicistronic tetracycline-regulated expression 
vectors, CD9 and CD82 cDNA fragments were amplified by PCR, digested 
with EcoRI–NotI, and the purified cDNA fragments were ligated into EcoRI–
NotI-digested pNRTIS-21 (provided by Frank D. Bohmer, Friedrich Schiller 
University, Germany). E-cadherin-GFP was a gift from Jennifer L. Stow (The 
University  of  Queensland,  Australia).  All  constructs  were  verified  by  se-
quencing. PCR primer sequence and conditions are available upon request. 
The following antibodies were used: anti-FLAG antibodies from Sigma- 
Aldrich;  anti-GFP  from  MBL;  anti-dephosphorylated  -catenin  (anti-ABC) 
clone 8E7 monoclonal antibody and anti-phosphotyrosine 4G10 platinum 
from Millipore; -catenin (H-102) from Santa Cruz Biotechnology, Inc.; anti-
HSP70 from Assay Design; anti–phospho--catenin (Ser33/37/Thr41) from 
Cell Signaling Technology; anti-cytochrome c, anti–flotillin-1, anti–E-cadherin 
clone 36, anti–mouse CD9, anti-adaptin , and anti-EEA1 from BD. The 
GW4869 compound was from Sigma-Aldrich.
Cell culture and transfection
HEK 293T, CHO cells, and PC3 cells were cultured in DME, MEM, Alpha 
medium, and RPMI 1640 medium supplemented with 10% fetal bovine   
serum, respectively. For transient transfection, HEK 293T and CHO cells were 
transfected using Lipofectamine 2000 (Invitrogen) according to the manufac-
turer’s instructions. PC3 cells were transfected with FuGENE HD (Roche).
Exosome purification
Exosomes were isolated according to a procedure previously described, with 
slight modifications (Thery et al., 2006). Cells were cultured in medium sup-
plemented with 10% depleted FBS (FBS was predepleted of bovine exosomes 
by ultracentrifugation at 100,000 g for 16 h at 4°C) for 24 h. The culture   
media was collected on ice and centrifuged at 2,000 g for 10 min to remove 
dead cells and then centrifuged at 10,000 g for 30 min to pellet any cellular 
debris. The resulting supernatant was then subjected to one 0.1-µm filtration 
step using 0.1 µm Supor Membrane (Pall Corporation). Exosomes that passed 
through this filtration step were pelleted by ultracentrifugation at 100,000 g 
for 70 min at 4°C. The exosome pellet was washed once in a large volume of 
PBS and resuspended in PBS for further analysis. Protein concentration was 
determined by a modified Bradford Assay (Bio-Rad Laboratories).
of -catenin and E-cadherin was lower in exosomes produced by 
CD9-transfected cells as compared with the concentrations of these 
proteins detected in exosomes prepared from CD82-transfected 
cells (Fig. 5, B and C). Because the suppression of Wnt signaling 
induced by CD9 expression is quantitatively similar to that induced 
by CD82 expression, it is possible that CD9 also inhibits Wnt sig-
naling through additional exosome-independent pathways.
In general, proteins are targeted to multivesicular bodies   
after they are endocytosed from the plasma membrane (Lakkaraju 
and  Rodriguez-Boulan,  2008).  The  best-characterized  mecha-
nisms for protein sorting to MVBs involves ubiquitination of the 
target protein and its subsequent oligomerization (Fang et al., 
2007; Zuccato et al., 2007; Lakkaraju and Rodriguez-Boulan, 
2008). Regulatory phosphorylation has also been demonstrated 
to drive the sorting of target proteins into multivesicular lyso-
somes (Zuccato et al., 2007). The E-cadherin complex is endo-
cytosed after tyrosine phosphorylation and ubiquitination (Fujita   
et al., 2002). Activation of a tyrosine kinase facilitates the inter-
action of E-cadherin with Hakai, an E3 ubiquitin ligase. Hakai 
mediates the ubiquitination of the E-cadherin complex and 
induces its endocytosis. Indeed, we find that CD82 expression in-
duced the tyrosine phosphorylation of E-cadherin (unpublished 
data). However, we could not detect a consequent increase in the 
ubiquitination of E-cadherin. This result might indicate that CD82 
induces the tyrosine phosphorylation on an E-cadherin tyrosine 
residue unrelated to the Hakai association.
A growing body of data suggests that interactions between 
ESCRT machinery and sorting motifs on target proteins can di-
rect proteins into exosomes. A recent study showed that an inter-
action between the tyrosine-based motif of the transferrin receptor 
and the ESCRT component Alix induced TfR sorting into exo-
somes (Géminard et al., 2004). The C-terminal tail of CD82 con-
tains potential tyrosine-based sorting sequences (Berditchevski 
and Odintsova, 2007). However, mutation of these motifs has no 
effect on its capacity to initiate exosome targeting of -catenin 
(unpublished data). Further experiments will be required to com-
pletely understand the precise mechanisms through which exo-
some sorting is mediated by CD82.
It has been shown that CD9-containing exosome-like vesi-
cles released from egg cells facilitate sperm–egg fusion. How-
ever, purified vesicles from CD9
/ eggs impaired sperm–egg 
fusion (Miyado et al., 2008). We find that dendritic cells isolated 
from CD9 knockout mice exhibited reduced exosome release. 
This result suggests the important role that tetraspanins play in 
exosome biogenesis in vivo. Thus, our results demonstrate a 
novel mechanism through which the -catenin pool is regulated 
by an export pathway. A model depicting this pathway is shown 
in Fig. 7 C. At steady state, tetraspanins are organized as sig-
naling complexes with E-cadherin at the plasma membrane. 
This signaling complex, including tetraspanins, E-cadherin, and 
-catenin, can be internalized and delivered to early endosomes. 
Exosome biogenesis begins with outward vesicle budding at the 
limiting membrane of endosomes, generating intraluminal vesi-
cles (ILVs). This compartment eventually matures into late endo-
somes, also known as MVBs. These MVBs then fuse with the 
plasma membrane and release their intraluminal vesicles, re-
ferred to as exosomes, which contain -catenin. The exosome JCB • VOLUME 190 • NUMBER 6 • 2010   1090
goat serum dilution buffer (GSDB; 16% goat serum, 0.3% Triton X-100,   
20 mM NaPi, pH 7.4, and 150 mM NaCl). FLAG-tagged tetraspanins 
were detected using rabbit anti-FLAG antibodies (Sigma-Aldrich) followed 
by FITC-conjugated goat anti–rabbit IgG (Sigma-Aldrich). -Catenin was 
detected with anti-dephosphorylated -catenin (anti-ABC) clone 8E7 mono-
clonal antibody followed by goat anti–mouse IgG (H+L) Alexa Fluor 594 
(Invitrogen), and stained coverslips were mounted in Aquamount (Lerner 
Laboratories) and visualized at room temperature with a microscope (Axio-
phot; Carl Zeiss, Inc.) using a 63x NA 1.4 apochromatic objective. Images 
were acquired with a digital camera (Axiocam HRm; Carl Zeiss, Inc.) and 
Axiovision software (Carl Zeiss, Inc.). Images were exported in TIFF format 
and were not subjected to any post-acquisition processing.
Online supplemental material
The online supplemental material includes five supplemental figures as noted 
in the text and titled as follows: Fig. S1 shows that expression of CD9 and 
CD82 inhibits Wnt/-catenin signaling activated by Wnt3a condition me-
dium. Fig. S2 shows that CD9 and CD82 inhibition of Wnt/-catenin signal-
ing is GSK-3 independent. Fig. S3 shows that exosome-associated -catenin 
resides within the lumens of exosome vesicles, and the TSAP6 and ESCRT 
pathways are not involved in CD82-induced exosome release of -catenin. 
Fig. S4 shows that CD82 interacts with -catenin. Fig. S5 shows that exo-
some release of -catenin is E-cadherin dependent, and disruption of CD9 
expression reduces exosome release in vivo. Online supplemental material is 
available at http://www.jcb.org/cgi/content/full/jcb.201002049/DC1.
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Generation of BMDC-derived exosomes
Bone marrow dendritic cells (BMDCs) were generated from CD9 WT vs. knock-
out mice (gift from Ira Mellman, Yale University, New Haven, CT). BM cells 
were cultured with RPMI 1640 (Invitrogen) supplemented with 10% FBS,   
2 mM l-glutamine, and 1% granulocyte/macrophage colony-stimulating factor 
(GM-CSF). Cells were counted, replated at the same number of cells per condi-
tion, and grown in fresh medium with 10% exosome-free FBS obtained by 
overnight ultracentrifugation (100,000 g) on d 6. DC supernatants were col-
lected on d 7 and exosome purification was performed as described above.
Luciferase reporter assay
HEK 293T cells grown in 24-well culture plates were transiently transfected at 
60–70% confluence with 0.2 µg of TOPflash TCF reporter plasmid, 0.02 µg 
of Renilla luciferase reporter (Promega; which was used to evaluate the effi-
ciency of transfection), and various expression plasmids as indicated for indi-
vidual experiments. The total quantity of DNA in the transfection mixes was 
adjusted to equal amounts with empty vector. 24 h after transfection, lucifer-
ase activities were measured using the Dual-Luciferase Reporter Assay System 
(Promega) and a luminometer according to the manufacture’s specifications. 
The firefly luciferase activity was normalized to Renilla luciferase activity.
Electron microscopy of exosomes
Electron microscopic analysis of exosomes was based on a previously de-
scribed protocol (Mears et al., 2004). The exosomes purified as described 
above were fixed by suspension in 2% wt/vol paraformaldehyde in 200 mM 
phosphate buffer (pH 7.4) and the suspended exosomes were dropped 
onto a formvar-carbon–coated grid and left to dry at room temperature for 
20 min. After washes in PBS, the exosomes were fixed in 1% gluteraldehyde 
for 5 min. After water washes, the exosome samples were stained with satu-
rated aqueous uranyl oxalate for 5 min. Samples were then embedded in 
0.4% wt/vol uranyl acetate, 1.8% wt/vol methylcellulose on ice for 10 min. 
The excess liquid was removed. The grid was dried at room temperature for 
10 min and viewed with an electron microscope (model 910; Carl Zeiss, 
Inc.) at 20,000x and 50,000x. Images were recorded on film and sub-
sequently scanned into TIFF format. Images were not subjected to any post-
acquisition processing.
Western blot analysis and immunoprecipitation
Cells were lysed with lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 
1 mM EDTA, 1 mM NaF, 1 mM Na3VO4, and complete protease inhibitor 
tablet) and the indicated detergents. Cell lysates were cleared by centrifu-
gation at 14,000 g for 20 min. Supernatant fractions were used for West-
ern blot or immunoprecipitation. For Western blot analysis, cell lysates and 
exosome fractions were resolved by SDS-PAGE and probed with the indi-
cated antibodies. For immunoprecipitation analysis, lysates were incubated 
overnight with the indicated antibody, followed by Western blotting. To de-
tect ubiquitination and tyrosine phosphorylation of E-cadherin, cells were 
lysed for 20 min in 1% Triton X-100 lysis buffer (20 mM Tris-HCl, pH 7.4, 
150 mM NaCl, 1 mM CaCl2, 10 mM N-ethylmaleimide, 1 mM PMSF, 1 mM 
NaF, and complete protease inhibitor tablet). After centrifugation at 14,000 g 
for 20 min, the supernatants were immunoprecipitated for 1 h with rabbit 
polyclonal anti-GFP antibody and immobilized protein G (Thermo Fisher 
Scientific), and the recovered proteins were analyzed by SDS-PAGE fol-
lowed by Western blotting with indicated antibodies.
Knockdown of CD9 expression using shRNA in HeLa cells
Two shRNAs encoding CD9-specific sequences and one shRNA encoding 
a control scrambled sequence were generated using the pSUPER.gfp/neo 
expression vector (OligoEngine) according to the manufacturer’s instruc-
tions. Oligonucleotides for short hairpin RNA (shRNA) are as follows: CD9 
target1  (CD9-1)  sense  strand,  5-GATCCCCGCACCAAGTGCATCAAA-
TACCTTCAAGAGAGGTATTTGATGCACTTGGTGCTTTTTA-3  and  antisense 
strand,  5-AGCTTAAAAAGCACCAAGTGCATCAAATACCTCTCTTGAAG-
GTATTTGATGCACTTGGTGCGGG-3; CD9 target2 (CD9-2) sense strand, 
5-GATCCCCACAGGAGTCTATATTCTGATCTTCAAGAGAGATCAGAATA-
TAGACTCCTGTTTTTTA-3 and antisense strand, 5-AGCTTAAAAAACAGG-
AGTCTATATTCTGATCTTCAAGAGAGATCAGAATATAGACTCCTGTGGG-3; 
Control  sense  strand,  5-GATCCCCGGTAAGCATTATCTTCAAGTCTTCA-
AGAGAGACTTGAAGATAATGCTTACCTTTTTA-3  and  antisense  strand, 
5-AGCTTAAAAAGGTAAGCATTATCTTCAAGTCTCTCTTGAAGACTTGAA-
GATAATGCTTACCGGG-3. CD9 target2 and control scrambled sequences 
have been described previously (Mitsuzuka et al., 2005).
Immunofluorescence microscopy
Transfected CHO cells were grown on glass coverslips, fixed with cold 
methanol, permeabilized with 0.3% Triton X-100, and then blocked with 1091 A novel mechanism that inhibits Wnt signaling • Chairoungdua et al.
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